| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.8 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |